Skip to main content
APGE
NASDAQ Life Sciences

Apogee Therapeutics 报告 2025 10-K 中 $0 收入，$(4.22) EPS 在大量研发投资中

feedReported by Unknown
Sentiment info
Negative
Importance info
7
Price
$69
Mkt Cap
$4.782B
52W Low
$26.2
52W High
$84.56
Market data snapshot near publication time

summarizeSummary

Apogee Therapeutics 提交了其 2025 10-K，报告无产品收入，净亏损为 255.8 万美元，导致 EPS 为 $(4.22)。该公司遭受了 285.6 万美元的营业亏损，反映了其在临床和制造计划中的大量投资。对于一家临床阶段的生物技术公司来说，$0 收入和重大亏损是典型的，因为它大量投资于其产品线。该年度报告提供了对公司财务业绩的全面了解，突出了其继续推进多个抗体计划的重点，包括 zumilokibart。投资者将监测公司的现金燃烧率及其继续为临床试验提供资金的能力，当它推进到潜在的商业化时。

在该公告发布时，APGE的交易价格为$69.00，交易所为NASDAQ，所属行业为Life Sciences，市值约为$47.8亿。 52周交易区间为$26.20至$84.56。 这则新闻被评估为消极市场情绪，重要性评分为7/10。 来源：Unknown。

show_chartPrice Chart

Share this article

Copied!

feed APGE - Latest Insights

APGE
Mar 25, 2026, 4:53 PM EDT
Source: Wiseek News
Importance Score:
9
$377.4M Equity Offering Finalized by Apogee Therapeutics, Underwriters Exercise Full Option
Sentiment: Neutral
View Wiseek Article
APGE
Mar 25, 2026, 4:44 PM EDT
Filing Type: 8-K
Importance Score:
8
Apogee Therapeutics Finalizes $402.5M Public Offering at $70.00/Share
Sentiment: Negative
View Wiseek Article
APGE
Mar 25, 2026, 4:40 PM EDT
Filing Type: 424B5
Importance Score:
8
Apogee Therapeutics Prices $350M Public Offering at $70.00/Share Following Positive Clinical Data
Sentiment: Neutral
View Wiseek Article
APGE
Mar 24, 2026, 9:54 PM EDT
Source: Reuters
Importance Score:
8
Apogee Therapeutics Prices $350M Offering at $70/Share Following Positive Trial Data
Sentiment: Neutral
View Wiseek Article
APGE
Mar 23, 2026, 4:28 PM EDT
Filing Type: 424B5
Importance Score:
8
Apogee Therapeutics Launches $300M Public Offering Following Positive Phase 2 Data
Sentiment: Neutral
View Wiseek Article
APGE
Mar 23, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Apogee Therapeutics Proposes $300M Public Offering Following Positive Clinical Data
Sentiment: Neutral
View Wiseek Article
APGE
Mar 23, 2026, 6:36 AM EDT
Filing Type: 8-K
Importance Score:
9
Apogee Therapeutics Reports Strong 52-Week Phase 2 Data for Zumilokibart in Atopic Dermatitis
Sentiment: Positive
View Wiseek Article
APGE
Mar 23, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Apogee's Zumilokibart Delivers Strong 52-Week Phase 2 Data in Atopic Dermatitis, Showing Durable Efficacy with Quarterly/Biannual Dosing
Sentiment: Positive
View Wiseek Article
APGE
Mar 02, 2026, 7:25 AM EST
Source: Unknown
Importance Score:
7
Apogee Therapeutics Reports $0 Revenue, $(4.22) EPS in 2025 10-K Amid Heavy R&D Investment
Sentiment: Negative
View Wiseek Article
APGE
Mar 02, 2026, 7:20 AM EST
Filing Type: 10-K
Importance Score:
9
Apogee Therapeutics Reports Strong Clinical Progress for Lead Candidate, Secures Long Runway into 2028
Sentiment: Positive
View Wiseek Article